Treatment with human recombinant chemerin promoted the invasiveness of gastric cancer cells by upregulating vascular endothelial growth factor, matrix metalloproteinase (MMP)-7 and interleukin-6 via phosphorylation of p38 and extracellular signal-regulated kinase1/2 MAPK [16] and by reducing the secreted levels of tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP2 via CMKLR1 and G protein-coupled receptor 1 [17]. Here, RARRES2 is linked to gastric cancer.